Shaolin Capital Management’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Shaolin Capital Management’s Portfolio NKGN Stock Details NKGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-200,000	Closed	-$2.03M	–	740
2023 Q1	$2.03M	Hold	200,000	–	–	0.06%	242
2022 Q4	$1.99M	Sell	200,000 -43,896	-18%	-$434K	0.06%	298
2022 Q3	$2.38M	Sell	243,896 -9,498	-4%	-$92.7K	0.07%	338
2022 Q2	$2.46M	Hold	253,394	–	–	0.06%	365
2022 Q1	$2.46M	Hold	253,394	–	–	0.06%	379
2021 Q4	$2.46M	Hold	253,394	–	–	0.06%	366
2021 Q3	$2.46M	Buy	+253,394	New	+$2.47M	0.07%	282

Other funds holding NKGN

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

FTCM

Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

SIM

Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

SFM

Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return

Shaolin Capital Management's NKGN Position: Q2 2023 in Review

Shaolin Capital Management sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q2 2023, closing a stake of 200,000 shares — an estimated $2.03M sold.

Shaolin Capital Management first reported a position in NKGN in Q3 2021 and held it in 7 quarters. The position peaked at $2.46M in Q2 2022. 25 funds tracked by Wall St. Rank hold NKGN as of Q2 2023.

Shaolin Capital Management reported no remaining NKGen Biotech, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Shaolin Capital Management sold 200,000 NKGen Biotech, Inc. Common Stock shares in Q2 2023, an estimated $2.03M.
Shaolin Capital Management first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
Shaolin Capital Management's NKGen Biotech, Inc. Common Stock position peaked at $2.46M in Q2 2022.
25 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q2 2023.

Based on Shaolin Capital Management's 13F filing for Q2 2023, filed 15 Aug 2023.